Free Trial
NASDAQ:HRTS

Tema Cardiovascular and Metabolics ETF (HRTS) Price, Holdings, & News

$30.72 -0.02 (-0.07%)
As of 02/21/2025 03:34 PM Eastern

About Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS)

Key Stats

Today's Range
$30.66
$30.95
50-Day Range
$28.67
$30.91
52-Week Range
$28.56
$36.03
Volume
4,589 shs
Average Volume
10,264 shs
Market Capitalization
$70.66 million
Assets Under Management
$70.89 million
Dividend Yield
1.50%
Net Expense Ratio
0.75%
Aggregate Rating
Moderate Buy

ETF Overview

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.

Tema Cardiovascular and Metabolics ETF Expenses

TypeHRTSTheme ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.99%0.57%0.56%0.51%0.53%
Other Expenses0.00%0.57%0.50%0.47%0.53%
Total Expense0.99%0.72%0.72%0.67%0.71%
Fee Waiver-0.24%-0.72%-0.50%-0.32%-0.56%
Net Expense0.75%0.60%0.62%0.60%0.60%
Receive HRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tema Cardiovascular and Metabolics ETF and its competitors with MarketBeat's FREE daily newsletter.

HRTS ETF News Headlines

HRT may help to protect the heart
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Oil Prices Spike Amid Middle East Tensions
Guardian Capital LP Launches Two New ETFs on CBOE Canada
See More Headlines

HRTS ETF - Frequently Asked Questions

Tema Cardiovascular and Metabolics ETF's stock was trading at $28.87 on January 1st, 2025. Since then, HRTS stock has increased by 6.4% and is now trading at $30.72.
View the best growth stocks for 2025 here
.

Top institutional shareholders of Tema Cardiovascular and Metabolics ETF include Sterling Investment Advisors Ltd. (7.29%).

Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Cardiovascular and Metabolics ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Barrick Gold (GOLD).

Fund Details

Issuer
Tema Global
Fund Name
Tema Cardiovascular and Metabolics ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:HRTS
Inception Date
11/20/2023
Fund Manager
David Song, Yuri Khodjamirian
Previous Symbol
NASDAQ:HRTS
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
44

Fund Statistics

Assets Under Management
$70.89 million
Average Daily Volume
$0.00
Discount/Premium
-0.08%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Tema Global Limited
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
N/A
Short Interest
1,500 shs

Miscellaneous

Beta
0.93
Creation Unit
10,000
Creation Fee
$500.00
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Top 10 HRTS Holdings

HRTS Sector Exposure

HRTS Industry Exposure


This page (NASDAQ:HRTS) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners